Alnylam Pharmaceuticals RNAi Roundtable Highlights Brezosiran's Exon 1 Approach for Huntington's Disease

The Quick Take

• Alnylam Pharmaceuticals hosted an RNAi roundtable focusing on Brezosiran's exon 1 targeting strategy for Huntington's disease treatment.
• Exon 1 targeting with RNAi represents a differentiated approach to silencing the HTT gene mutation that causes Huntington's, with potentially broader efficacy than allele-specific methods.
• Brezosiran's clinical progress positions Alnylam as a leader in applying its validated RNAi platform to CNS diseases beyond its cardiovascular stronghold.

Alnylam Pharmaceuticals hosted an investor and scientific roundtable on October 26, 2026 featuring its Brezosiran programme for Huntington's disease, with a specific focus on the exon 1 targeting strategy. Huntington's is caused by a CAG repeat expansion in exon 1 of the HTT gene; targeting this region with RNAi offers the potential for allele-nonspecific gene silencing — reducing both mutant and wild-type huntingtin. Alnylam, whose commercial RNAi franchise includes Onpattro, Givlaari, and Oxlumo, is leveraging its established delivery technology to enter the large CNS disease market where no disease-modifying therapy currently exists at scale.

The strategic significance of Brezosiran for Alnylam's pipeline is substantial. Huntington's disease affects approximately 30,000 patients in the US with no approved disease-modifying treatment; a successful RNAi therapy would command premium pricing and establish a CNS franchise alongside the existing liver-targeted franchise. Wave Life Sciences and uniQure are competing in the Huntington's space with gene therapy approaches, while Roche's tominersen, an antisense oligonucleotide that failed in 2021, demonstrated the challenge of CNS drug delivery. Alnylam's GalNAc delivery system, which excels at liver delivery, may require adaptation for CNS applications.

The watch point is Brezosiran's Phase 2 or Phase 3 clinical readout timeline. Huntington's trials are long and expensive — endpoint achievement takes years due to the disease's slow progression. Watch for Alnylam's next clinical update disclosing patient recruitment completion, biomarker data showing HTT protein lowering in CSF, and safety signals from dose escalation. The macro variable for Alnylam's stock is the broader RNAi and gene therapy sector sentiment, which is highly correlated with FDA approval rates and headline trial outcomes from platform competitors.

Synthesized from 1 source.